Şunu aradınız:: hipertrofije (Slovence - İngilizce)

zdravljenje benigne hipertrofije prostate pri psih samcih.
treatment of benign prostatic hypertrophy in male dogs.

poleg hipertrofije hepatocitov niso opazili drugih histopatoloških sprememb.
apart from the hypertrophy of hepatocytes, no other histopathologic changes were observed.

zdravljenje benigne hipertrofije prostate (bhp) pri psih samcih.
treatment of benign prostatic hypertrophy (bph) in male dogs.

zdravljenje z zdravilom ypozane je bilo pri zdravljenju benigne hipertrofije prostate učinkovito.
treatment with ypozane was effective in the treatment of benign prostatic hypertrophy.

opažali so pojav hipertrofije (vključno z lipohipertrofijo) na mestu injiciranja.
occurrence of injection site hypertrophy has been observed, including lipohypertrophy.

pokazali so, da zdravljenje s tabletami doksazosina s takojšnjim sproščanjem povzroča regresijo hipertrofije levega prekata.
treatment with doxazosin immediate release tablets has been shown to result in regression of left ventricular hypertrophy.

oksibutinin lahko poslabša simptome hipertiroidizma, koronarne srčne bolezni, kongestivnega srčnega popuščanja, srčnih aritmij, tahikardije, hipertenzije in hipertrofije prostate.
oxybutynin may exacerbate the symptoms of hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, tachycardia, hypertension and prostatic hypertrophy

varnostni podatki, pridobljeni pri teh bolnikih, ne nakazujejo posebnih težav z varnostjo in potrjujejo manjšo pogostnost hipertrofije, kot nakazuje znanstvena literatura o uporabi kolagenskih membran v primerjavi s periostom.
the safety data obtained in these patients do not indicate a particular safety concern, and confirm a lower incidence of hypertrophy as suggested by scientific literature on the use of collagen membranes versus periost.

možen pomen za klinično uporabo je naslednji: jetrne spremembe, ki bi se lahko kazale kot prilagoditveni odgovor s povečanjem mase in centrolobularne hipertrofije jeter, maščobna infiltracija v jetrih in zvišanje jetrnih encimov v plazmi.
adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma.

prav tako lahko tudi pokaže, da je prišlo do odebelitve srčne mišice (hipertrofije levega prekata), ali da je srce predhodno doživelo manjšo motnjo, kot je tih srčen infarkt.
jnc7 (2003) uses the term prehypertension for blood pressure in the range 120-139 mmhg systolic and/or 80-89 mmhg diastolic, while esh-esc guidelines (2007) and bhs iv (2004) use optimal, normal and high normal categories to subdivide pressures below 140 mmhg systolic and 90 mmhg diastolic.

pri izpostavljenosti, ki je bila za valsartan od 8- do 13-krat večja in za amlodipin od 7- do 8-krat večja kot ob kliničnih odmerkih 160 mg valsartana in 10 mg amlodipina, so ugotovili večjo pojavnostjo in izrazitost bazofilije/hialinizacije, dilatacije in cilindrov ledvičnih tubulov ter intersticijskega limfocitnega vnetja in hipertrofije arteriolarne medije.
an increased incidence and severity of renal tubular basophilia/hyalinisation, dilation and casts, as well as interstitial lymphocyte inflammation and arteriolar medial hypertrophy were found at an exposure of 8–13 (valsartan) and 7–8 (amlodipine) times the clinical doses of 160 mg valsartan and 10 mg amlodipine.